Heterodimerization of β2 adrenergic receptor and somatostatin receptor 5: Implications in modulation of signaling pathway

Journal of Molecular Signaling

Volumn 6, Issue , 2011, Pages

  Somvanshi, Rishi K ^a   Chaudhari, Nicole ^a   Qiu, Xiaofan ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

2 Adrenergic receptors; G protein coupled receptor; Heterodimerization; Human somatostatin receptor 5 ; Photobleaching fluorescence resonance energy transfer and Somatostatin

Indexed keywords

EID: 80051592695     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-6-9     Document Type: Article

References (57)

1. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 2007, 19:2304-2316. 10.1016/j.cellsig.2007.07.007, 17706924.
2. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288:154-157. 10.1126/science.288.5463.154, 10753124.
3. Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal 2009, 21:428-439. 10.1016/j.cellsig.2008.11.012, 19070659.
4. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002, 277:19762-19772. 10.1074/jbc.M110373200, 11896051.
5. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002, 87:5545-5552. 10.1210/jc.2002-020934, 12466351.
6. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355:2558-2573. 10.1056/NEJMra062453, 17167139.
7. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000, 97:3684-3689. 10.1073/pnas.060590697, 16300, 10725388.
8. Breit A, Lagace M, Bouvier M. Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 2004, 279:28756-28765. 10.1074/jbc.M313310200, 15123695.
9. Cao TT, Brelot A, von Zastrow M. The composition of the beta-2 adrenergic receptor oligomer affects its membrane trafficking after ligand-induced endocytosis. Mol Pharmacol 2005, 67:288-297. 10.1124/mol.104.003608, 15492118.
10. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, Crow MT. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res 2000, 87:1172-1179.
11. Hebert TE, Bouvier M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol 1998, 76:1-11. 10.1139/o98-012, 9666301.
12. Hebert TE, Loisel TP, Adam L, Ethier N, Onge SS, Bouvier M. Functional rescue of a constitutively desensitized beta2AR through receptor dimerization. Biochem J 1998, 330(Pt 1):287-293. 1219139, 9461522.
13. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 1996, 271:16384-16392. 10.1074/jbc.271.27.16384, 8663163.
14. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999, 100:2210-2212.
15. Hammond HK. Mechanisms for myocardial beta-adrenergic receptor desensitization in heart failure. Circulation 1993, 87:652-654.
16. Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, Devic E, Kobilka BK, Cheng H, Xiao RP. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 2003, 111:617-625. 151893, 12618516.
17. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 2001, 98:1607-1612. 10.1073/pnas.98.4.1607, 29304, 11171998.
18. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999, 274:16694-16700. 10.1074/jbc.274.24.16694, 10358008.
19. Rohrer DK. Physiological consequences of beta-adrenergic receptor disruption. J Mol Med 1998, 76:764-772. 10.1007/s001090050278, 9826121.
20. Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG, Balmforth AJ. Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol 2005, 187:379-386. 10.1677/joe.1.06082, 16423817.
21. Bell D, Zhao Y, McMaster B, McHenry EM, Wang X, Kelso EJ, McDermott BJ. SRIF receptor subtype expression and involvement in positive and negative contractile effects of somatostatin-14 (SRIF-14) in ventricular cardiomyocytes. Cell Physiol Biochem 2008, 22:653-664. 10.1159/000185549, 19088447.
22. Murray F, Bell D, Kelso EJ, Millar BC, McDermott BJ. Positive and negative contractile effects of somatostatin-14 on rat ventricular cardiomyocytes. J Cardiovasc Pharmacol 2001, 37:324-332. 10.1097/00005344-200103000-00011, 11243423.
23. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007, 25:297-308. 10.1016/j.nbd.2006.09.016, 1850107, 17126554.
24. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 2008, 22:2278-2292. 10.1210/me.2007-0334, 18653781.
25. Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 2004, 279:38636-38643. 10.1074/jbc.M406276200, 15247250.
26. Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 2003, 64:1317-1324. 10.1124/mol.64.6.1317, 3125687, 14645661.
27. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 2001, 98:343-348. 10.1073/pnas.011384898, 14592, 11134510.
28. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, Hebert TE. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 2002, 277:35402-35410. 10.1074/jbc.M204163200, 12140284.
29. Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem 2003, 278:10770-10777. 10.1074/jbc.M207968200, 12529373.
30. Zhu WZ, Chakir K, Zhang S, Yang D, Lavoie C, Bouvier M, Hebert TE, Lakatta EG, Cheng H, Xiao RP. Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res 2005, 97:244-251. 10.1161/01.RES.0000176764.38934.86, 16002745.
31. Niehoff DL, Mudge AW. Somatostatin alters beta-adrenergic receptor-effector coupling in cultured rat astrocytes. Embo J 1985, 4:317-321. 554188, 2862027.
32. Barber DL, McGuire ME, Ganz MB. Beta-adrenergic and somatostatin receptors regulate Na-H exchange independent of cAMP. J Biol Chem 1989, 264:21038-21042.
33. Mayor F, Benovic JL, Caron MG, Lefkowitz RJ. Somatostatin induces translocation of the beta-adrenergic receptor kinase and desensitizes somatostatin receptors in S49 lymphoma cells. J Biol Chem 1987, 262:6468-6471.
34. Somvanshi R, Qiu X, Kumar U. Role of Somatostatin in Modulation of β-Adrenergic Receptor Mediated Downstream Signaling Pathways in H9c2 Cells. ENDO 2011 2011, 4-7. Boston, MA.
35. Somvanshi RK, War SA, Chaudhari N, Qiu X, Kumar U. Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta(1)-adrenergic receptor and somatostatin receptor-5. Cell Signal 2011, 23:794-811. 10.1016/j.cellsig.2011.01.002, 21238583.
36. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282:737-740.
37. Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal 2009, 21:1396-1414. 10.1016/j.cellsig.2009.04.007, 19426801.
38. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996, 137:4046-4049. 10.1210/en.137.9.4046, 8756582.
39. Martin NP, Whalen EJ, Zamah MA, Pierce KL, Lefkowitz RJ. PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. Cell Signal 2004, 16:1397-1403. 10.1016/j.cellsig.2004.05.002, 15381255.
40. Fukushima N, Kohno M, Kato T, Kawamoto S, Okuda K, Misu Y, Ueda H. Melittin, a metabostatic peptide inhibiting Gs activity. Peptides 1998, 19:811-819. 10.1016/S0196-9781(98)00027-8, 9663445.
41. Mukai H, Munekata E, Higashijima T. G protein antagonists. A novel hydrophobic peptide competes with receptor for G protein binding. J Biol Chem 1992, 267:16237-16243.
42. Burns DL. Subunit structure and enzymic activity of pertussis toxin. Microbiol Sci 1988, 5:285-287.
43. Kumar U, Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ 2010, 50:137-184.
44. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91. 10.1038/36362, 9363896.
45. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 2003, 111:1475-1486. 155046, 12750397.
46. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. Embo J 2003, 22:5079-5089. 10.1093/emboj/cdg474, 204458, 14517246.
47. Pello OM, Martinez-Munoz L, Parrillas V, Serrano A, Rodriguez-Frade JM, Toro MJ, Lucas P, Monterrubio M, Martinez AC, Mellado M. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur J Immunol 2008, 38:537-549. 10.1002/eji.200737630, 18200497.
48. Banning C, Votteler J, Hoffmann D, Koppensteiner H, Warmer M, Reimer R, Kirchhoff F, Schubert U, Hauber J, Schindler M. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One 2010, 5:e9344. 10.1371/journal.pone.0009344, 2825263, 20179761.
49. Prinster SC, Hague C, Hall RA. Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 2005, 57:289-298. 10.1124/pr.57.3.1, 16109836.
50. Prinster SC, Holmqvist TG, Hall RA. Alpha2C-adrenergic receptors exhibit enhanced surface expression and signaling upon association with beta2-adrenergic receptors. J Pharmacol Exp Ther 2006, 318:974-981. 10.1124/jpet.106.106526, 16757535.
51. Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept 2010, 159:3-8. 10.1016/j.regpep.2009.08.011, 19748526.
52. Iwai-Kanai E, Hasegawa K. Intracellular signaling pathways for norepinephrine- and endothelin-1-mediated regulation of myocardial cell apoptosis. Mol Cell Biochem 2004, 259:163-168.
53. Zamir E, Lommerse PH, Kinkhabwala A, Grecco HE, Bastiaens PI. Fluorescence fluctuations of quantum-dot sensors capture intracellular protein interaction dynamics. Nat Methods 2010, 7:295-298. 10.1038/nmeth.1441, 20228813.
54. Zheng M, Hou R, Han Q, Xiao RP. Different regulation of ERK1/2 activation by beta-adrenergic receptor subtypes in adult mouse cardiomyocytes. Heart Lung Circ 2004, 13:179-183. 10.1016/j.hlc.2004.02.018, 16352191.
55. Antoni FA, Palkovits M, Simpson J, Smith SM, Leitch AL, Rosie R, Fink G, Paterson JM. Ca2+/calcineurin-inhibited adenylyl cyclase, highly abundant in forebrain regions, is important for learning and memory. J Neurosci 1998, 18:9650-9661.
56. Kashishian A, Howard M, Loh C, Gallatin WM, Hoekstra MF, Lai Y. AKAP79 inhibits calcineurin through a site distinct from the immunophilin-binding region. J Biol Chem 1998, 273:27412-27419. 10.1074/jbc.273.42.27412, 9765270.
57. Lee S, Wishart MJ, Williams JA. Identification of calcineurin regulated phosphorylation sites on CRHSP-24. Biochem Biophys Res Commun 2009, 385:413-417. 10.1016/j.bbrc.2009.05.096, 2740617, 19477163.